Skip to main content
Psychedexbeta

4-PrO-DMT

Summary

4-PrO-DMT (4-propionyloxy-N,N-dimethyltryptamine) is an emerging synthetic psychedelic of the tryptamine class. It is a prodrug of psilocin — the same active compound that psilocybin and psilacetin both deliver.[1] It activates serotonin receptors in the brain, producing the visual and cognitive shifts characteristic of classical psychedelics.[2]

Entity
4-PrO-DMT
PSX-0429
4-PrO-DMT 2D chemical structure
Open Beta

Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.

Common names4-PrO-DMT, 4-Propionoxy-DMT, O-Propionylpsilocin, 4-Propionoyloxy-N,N-dimethyltryptamine, 4-Propanoyloxy-DMT
PsychoactivePsychedelic
+1 moreEntheogen
ChemicalSubstituted tryptamine
Light
5 – 10 mg
Common
10 – 25 mg
Strong
25 – 45 mg
Heavy
45+ mg
12340 h2 h4 h5 h
1Onset
20m–40m2Come-up
20m–40m3Peak
2h–3h4Resolution
1h–2h5Aftereffects
2h–6h
Total4h–8h
minlowmodhigh
Acute
Chronic
Physical
Psych.
Withdrawal
Builduprapid
Full reset14 days
Cross-tol.
psilocybin, psilocin, 4-AcO-DMT +3 more
Absolute4 entries
Absolute contraindication: Lithium
Concurrent lithium use with classic serotonergic psychedelics carries an alarmingly high seizure rate (47% of 62 analyzed reports). The mechanism remains unidentified. This is classified as an absolute contraindication for all psilocin-class compounds, including 4-PrO-DMT. Lamotrigine does not carry this risk (0/34 reports involved seizures), suggesting the interaction is lithium-specific rather than a general mood-stabilizer effect.
Absolute contraindication: Psychotic spectrum or bipolar I disorder
Serotonergic psychedelics potently activate 5-HT2A receptors on cortical pyramidal neurons, disrupting thalamocortical gating and increasing neural entropy. In individuals with latent or active psychotic vulnerability, this can precipitate prolonged psychotic episodes, mania, or exacerbation of existing symptoms. Risk extends to first-degree family history of these conditions. This is a class-level contraindication established for the psilocin/psilocybin pharmacological class and applied to 4-PrO-DMT by structural analogy as a psilocin prodrug.
Absolute contraindication: Pregnancy or breastfeeding
No published safety data exist for 4-PrO-DMT, psilocin, or psilocybin during pregnancy or breastfeeding. The serotonin system plays critical roles in fetal neurodevelopment, and 5-HT2A agonism carries theoretical risk of developmental disruption. Classified as an absolute contraindication based on absence of safety data.
Absolute contraindication: Monoamine oxidase inhibitors (MAOIs)
Monoamine oxidase inhibitors block the MAO-A-mediated deamination pathway for psilocin (the active metabolite of 4-PrO-DMT), causing serotonin accumulation and risk of serotonin toxicity. A case report documented hypertensive emergency and myocardial infarction in a patient on tranylcypromine and dextroamphetamine who consumed psilocybin mushrooms. For synthetic 4-PrO-DMT (which lacks mushroom-derived phenylethylamines), the primary MAOI risk is serotonin toxicity via impaired 5-HT metabolism. This constitutes both a pharmacokinetic amplifier and a pharmacodynamic hazard.
Relative4 entries
Relative contraindication: Active cardiovascular disease
Psilocin-class psychedelics produce transient dose-dependent increases in systolic blood pressure and heart rate. For 4-PrO-DMT specifically, the atypically potent 5-HT2B binding (Ki = 17 nM) introduces additional uncertainty, as chronic 5-HT2B agonism is the established mechanism for cardiac valvulopathy associated with fenfluramine and ergotamine. Three mitigating factors apply: rapid prodrug conversion to psilocin (lower 5-HT2B affinity), typically intermittent psychedelic use patterns, and relative cardiovascular safety observed in clinical psilocybin studies. Whether the intact prodrug engages cardiac 5-HT2B before hydrolysis remains unresolved.
— no data —
Dosage varies by body weight, tolerance & metabolism · Not medical advice · Terms
See an error? Suggest correction

The concept of psilocin ester prodrugs traces to a 1963 patent by Albert Hofmann, though 4-PrO-DMT was not specifically named.[3] It appeared on research chemical markets in May 2019 and was flagged by Swedish authorities two months later.[3] It remains a niche research chemical — explicitly controlled in the United Kingdom and Sweden, but unscheduled in most jurisdictions.

Subjective effects include geometric visual patterns, brightened colors, deepened introspection, ego dissolution, and emotional intensification.[4] The experience is indistinguishable from psilocybin or psilacetin — a warm, inward-turning state shaped more by psychological mindset and surroundings than by the compound itself. Nausea during onset, looping thoughts, and acute anxiety are the most commonly reported unwanted effects.

4-PrO-DMT produces no physical dependence, and the psilocin class has a very wide margin between active and dangerous doses.[5][3] The primary risk is psychological — the compound amplifies whatever mindset the person brings, and high doses or psychiatric vulnerability can produce panic or paranoid thinking. No controlled human studies exist — the current understanding rests on a 2023 mouse study and analogy to psilocybin.[2]

History[edit]

Discovery

Albert Hofmann and Franz Troxler's 1963 Sandoz patent described a family of psilocin ester prodrugs — the same series that includes psilacetin.[3] The propionyl variant went unnamed. The compound attracted no scientific interest for fifty years.

Emergence and identification

May 2019 brought its debut on research chemical markets — positioned as an unscheduled psilocybin substitute alongside similar analogs.[3][2][6] Sweden's drug surveillance system classified it as a novel psychoactive substance two months later.[3]

First pharmacological study

In April 2023, Glatfelter et al. completed the first scientific characterization: receptor binding data, a crystal structure, and behavioral results from mouse studies.[2] No human trials are registered or planned as of September 2026.

Chemistry[edit]

Structure

4-PrO-DMT is built on the tryptamine backbone[7] — the bicyclic indole scaffold shared by serotonin and DMT. Two methyl groups sit on the terminal amine, and the 4-position of the indole ring carries a propionyloxy ester. Enzymes cleave that ester bond to release psilocin as the active compound.[2]

Molecular formulaC₁₅H₂₀N₂O₂
Molecular weight260.33 g/mol

Structural relationships

4-PrO-DMT belongs to a series of psilocin prodrugs differing by acyl chain length: psilacetin has two carbons, 4-PrO-DMT has three. psilocybin achieves the same conversion via a phosphate ester instead of a carboxylate ester.[1] The longer chain may slightly increase lipophilicity and slow ester cleavage, though no pharmacokinetic data confirm this for 4-PrO-DMT specifically.[8] The molecule has no stereocenters.[2]

Pharmacology[edit]

Mechanism of action

The compound is inactive until enzymes strip the propionyl ester from the indole ring, releasing psilocin.[2][9][8] Psilocin is the same active compound that psilocybin and psilacetin generate through their own hydrolysis routes.[1]

Psilocin activates serotonin receptors on cortical neurons, producing the psychedelic effect. Mouse studies confirm this: 4-PrO-DMT triggers the standard behavioral marker of psychedelic activity at 0.3–3 mg/kg (subcutaneous), and a selective serotonin receptor blocker eliminates the response entirely.[2]

Pharmacokinetics

4-PrO-DMT has no published human pharmacokinetic data. After conversion, psilocin peaks in the bloodstream roughly 2–4 hours after oral dosing, with bioavailability near 50% and an elimination half-life of 1.5–4 hours.[10][11] inferred All figures come from psilocybin studies; the propionyl ester's extra hydrolysis step may push onset later — by how much remains unknown.[10][11]

Neuroscience[edit]

Where it acts

No neuroimaging data exist for 4-PrO-DMT. Because it converts to psilocin, its brain effects match what psilocybin research describes — the active molecule at brain receptors is identical. Psilocin activates serotonin receptors on cortical neurons, disrupting the brain's default mode network and loosening sensory filtering — producing altered self-boundaries, unusual associative thinking, and perceptual distortion.[12][13]

Why it matters

Activating cortical serotonin receptors triggers growth-factor pathways that increase synaptic branching — a form of neuroplasticity.[13] The REBUS model proposes that this temporarily loosens entrenched cognitive patterns, opening a window where rigid mental habits can be revised.[13] Whether 4-PrO-DMT produces identical changes has not been tested; the shared active metabolite makes it a reasonable expectation.

4-PrO-DMT (4-propionyloxy-N,N-dimethyltryptamine) is an emerging synthetic psychedelic of the tryptamine class. It is a prodrug of psilocin, the same active metabolite delivered by psilocybin and psilacetin.[1] 4-PrO-DMT acts as a 5-HT₂A receptor agonist through psilocin, producing its effects by altering serotonin-mediated sensory and cognitive processing.[2]

Entity
4-PrO-DMT
PSX-0429
4-PrO-DMT 2D chemical structure
Open Beta

Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.

Common names4-PrO-DMT, 4-Propionoxy-DMT, O-Propionylpsilocin, 4-Propionoyloxy-N,N-dimethyltryptamine, 4-Propanoyloxy-DMT
PsychoactivePsychedelic
+1 moreEntheogen
ChemicalSubstituted tryptamine
Light
5 – 10 mg
Common
10 – 25 mg
Strong
25 – 45 mg
Heavy
45+ mg
12340 h2 h4 h5 h
1Onset
20m–40m2Come-up
20m–40m3Peak
2h–3h4Resolution
1h–2h5Aftereffects
2h–6h
Total4h–8h
minlowmodhigh
Acute
Chronic
Physical
Psych.
Withdrawal
Builduprapid
Full reset14 days
Cross-tol.
psilocybin, psilocin, 4-AcO-DMT +3 more
Absolute4 entries
Absolute contraindication: Lithium
Concurrent lithium use with classic serotonergic psychedelics carries an alarmingly high seizure rate (47% of 62 analyzed reports). The mechanism remains unidentified. This is classified as an absolute contraindication for all psilocin-class compounds, including 4-PrO-DMT. Lamotrigine does not carry this risk (0/34 reports involved seizures), suggesting the interaction is lithium-specific rather than a general mood-stabilizer effect.
Absolute contraindication: Psychotic spectrum or bipolar I disorder
Serotonergic psychedelics potently activate 5-HT2A receptors on cortical pyramidal neurons, disrupting thalamocortical gating and increasing neural entropy. In individuals with latent or active psychotic vulnerability, this can precipitate prolonged psychotic episodes, mania, or exacerbation of existing symptoms. Risk extends to first-degree family history of these conditions. This is a class-level contraindication established for the psilocin/psilocybin pharmacological class and applied to 4-PrO-DMT by structural analogy as a psilocin prodrug.
Absolute contraindication: Pregnancy or breastfeeding
No published safety data exist for 4-PrO-DMT, psilocin, or psilocybin during pregnancy or breastfeeding. The serotonin system plays critical roles in fetal neurodevelopment, and 5-HT2A agonism carries theoretical risk of developmental disruption. Classified as an absolute contraindication based on absence of safety data.
Absolute contraindication: Monoamine oxidase inhibitors (MAOIs)
Monoamine oxidase inhibitors block the MAO-A-mediated deamination pathway for psilocin (the active metabolite of 4-PrO-DMT), causing serotonin accumulation and risk of serotonin toxicity. A case report documented hypertensive emergency and myocardial infarction in a patient on tranylcypromine and dextroamphetamine who consumed psilocybin mushrooms. For synthetic 4-PrO-DMT (which lacks mushroom-derived phenylethylamines), the primary MAOI risk is serotonin toxicity via impaired 5-HT metabolism. This constitutes both a pharmacokinetic amplifier and a pharmacodynamic hazard.
Relative4 entries
Relative contraindication: Active cardiovascular disease
Psilocin-class psychedelics produce transient dose-dependent increases in systolic blood pressure and heart rate. For 4-PrO-DMT specifically, the atypically potent 5-HT2B binding (Ki = 17 nM) introduces additional uncertainty, as chronic 5-HT2B agonism is the established mechanism for cardiac valvulopathy associated with fenfluramine and ergotamine. Three mitigating factors apply: rapid prodrug conversion to psilocin (lower 5-HT2B affinity), typically intermittent psychedelic use patterns, and relative cardiovascular safety observed in clinical psilocybin studies. Whether the intact prodrug engages cardiac 5-HT2B before hydrolysis remains unresolved.
— no data —
Dosage varies by body weight, tolerance & metabolism · Not medical advice · Terms
See an error? Suggest correction

The concept of psilocin ester prodrugs traces to a 1963 Sandoz patent by Albert Hofmann and Franz Troxler, though 4-PrO-DMT itself was not named in the original filing.[3] The compound first appeared on research chemical markets in May 2019 and was identified as a new psychoactive substance by Swedish authorities two months later.[3] It remains a niche research chemical with limited circulation, explicitly controlled in the United Kingdom and Sweden but unscheduled in most other jurisdictions.

Subjective effects include geometric visual patterns, enhanced color saturation, deepened introspection, ego dissolution, and emotional intensification.[4] The experience is reported as qualitatively indistinguishable from psilocybin or psilacetin — a warm, inward-turning psychedelic state shaped more by psychological set and setting than by the compound itself. Nausea during onset, thought loops, and acute anxiety are commonly reported unsought effects.

4-PrO-DMT produces no physical dependence, and the psilocin class has extremely low acute toxicity — the margin between active and lethal doses is wide, and no human fatalities have been attributed to the compound.[5][3] The primary risk is psychological: high doses or psychiatric vulnerability can trigger acute panic, paranoid ideation, or transient psychotic symptoms, with severity scaling by dose and predisposition. No controlled human studies exist; the current understanding rests on a single 2023 mouse pharmacology study and structural analogy to psilocybin.[2]

History[edit]

Discovery

The foundation for 4-PrO-DMT lies in a 1963 Sandoz patent by Albert Hofmann and Franz Troxler, which covered a series of 4-position ester prodrugs of psilocin — including psilacetin.[3] The propionyl ester was not specifically named in that filing, and no academic attention followed for over five decades.

Emergence and identification

4-PrO-DMT first surfaced on online research chemical markets in May 2019, sold as an unscheduled alternative to psilocybin alongside other psilocin prodrug analogs.[3][2][6] Swedish drug monitoring authorities identified it as a new psychoactive substance in July 2019, marking its first documented encounter in a national surveillance system.[3]

First pharmacological study

The first formal scientific characterization appeared in April 2023, when Glatfelter et al. published receptor binding profiles, a crystal structure, and behavioral data in mice — a collaboration between CaaMTech, the University of Massachusetts Dartmouth, and the NIDA Intramural Research Program.[2] No clinical trials have been registered as of September 2026, and no controlled human studies are publicly planned.

Chemistry[edit]

Structure

4-PrO-DMT is built on the tryptamine backbone — a bicyclic indole ring fused to an ethylamine side chain — shared by endogenous serotonin and N,N-dimethyltryptamine.[7] Two modifications define the molecule: the terminal amine carries two methyl groups (N,N-dimethylation), and the 4-position of the indole ring bears a propionyloxy ester — a three-carbon acyl group linked through an oxygen to the ring. This ester bond is the prodrug mechanism: enzymes cleave it to expose the 4-hydroxyl group of psilocin.[2]

Molecular formulaC₁₅H₂₀N₂O₂
Molecular weight260.33 g/mol

Structural relationships

4-PrO-DMT belongs to a homologous series of psilocin 4-acyloxy prodrugs distinguished by acyl chain length. Psilacetin carries a two-carbon acetyl group; 4-PrO-DMT extends this by one methylene unit to a three-carbon propionyl group. psilocybin achieves the same prodrug function through a phosphate ester rather than a carboxylate ester.[1]

The longer acyl chain is expected to modestly increase lipophilicity and may influence how quickly the ester is cleaved, though no published data confirm altered pharmacokinetics for 4-PrO-DMT specifically.[8]

Stereochemistry and physical properties

The molecule contains no stereocenters and is achiral.[2] Research-grade material (as the hydrofumarate salt) presents as a white to off-white crystalline solid.[9] The crystal structure was determined by X-ray diffraction and is reported in the primary pharmacology study.[2]

No melting point, partition coefficient, or aqueous solubility at physiological pH has been published. Stability under ambient conditions and degradation pathways have not been characterized.

Pharmacology[edit]

Mechanism of action

4-PrO-DMT is a prodrug. Plasma and tissue esterases cleave the propionyl ester at the 4-position of the indole ring, releasing psilocin as the pharmacologically active metabolite.[2][10][8] This parallels how psilocybin is converted to psilocin by phosphatase enzymes, and how psilacetin is converted by the same esterase hydrolysis pathway.[1]

Psilocin produces its psychedelic effects primarily through agonism at 5-HT₂A receptors on cortical neurons. In mice, 4-PrO-DMT triggers the head-twitch response — a standard proxy for psychedelic activity — at doses of 0.3–3 mg/kg (subcutaneous), and this response is fully blocked by the selective 5-HT₂A antagonist M100907.[2]

At higher doses (≥3 mg/kg), concurrent activation of 5-HT₁A receptors produces sedation and drops in body temperature, which partially suppress the head-twitch response — a pattern consistent with the interplay between excitatory and inhibitory serotonin pathways observed across tryptamine psychedelics.[2][11]

Pharmacokinetics

No human pharmacokinetic data exist for 4-PrO-DMT. The parameters below are derived from psilocin studies following psilocybin administration and are applicable by structural analogy.[12][13]

The prodrug undergoes hydrolysis by plasma and tissue esterases to yield psilocin.[2][10] The rate at which the propionyl ester is cleaved relative to the acetyl ester of psilacetin or the phosphate ester of psilocybin has not been published. General ester chemistry suggests the propionyl group may hydrolyze more slowly, potentially affecting onset timing — but this remains unconfirmed.

Once liberated, psilocin reaches peak plasma levels within approximately 2–4 hours of oral dosing, with an oral bioavailability around 50% and an elimination half-life of 1.5–4 hours.[12][13] Psilocin is cleared primarily through conjugation and oxidative metabolism; genetic variation in the relevant enzymes does not significantly alter psilocin blood levels.[13] inferred These values describe psilocin following psilocybin administration; timing for 4-PrO-DMT may differ because the propionyl ester hydrolysis step adds an unquantified delay.

Neuroscience[edit]

Where it acts

No direct neuroimaging or electrophysiology data have been published for 4-PrO-DMT. As a prodrug of psilocin, its neural effects are inferred from psilocybin research, where the active agent reaching brain receptors is identical. Psilocin engages 5-HT₂A receptors concentrated on cortical pyramidal neurons, disrupting the brain's default mode network and loosening thalamocortical gating — changes that underlie the dissolution of ordinary self-boundaries, novel associative thinking, and perceptual distortion.[14][15] PET imaging shows that subjective intensity tracks directly with receptor occupancy, reaching up to 72% at psychedelic doses.[16]

Why it matters

Psilocin-class compounds promote structural changes in brain connectivity. Activation of cortical 5-HT₂A receptors stimulates growth-factor signaling cascades that increase dendritic branching and the density of synaptic connections.[15] These neuroplastic effects are hypothesized to underlie the therapeutic potential of psychedelics — the REBUS model proposes that psychedelics temporarily relax entrenched cognitive patterns, opening a window in which rigid mental habits can be revised.[15]

Whether psilocin delivered via 4-PrO-DMT produces identical neuroplastic changes has not been specifically tested, but the shared active metabolite makes this a reasonable expectation.

Subjective Effects[edit]

Summary

The 4-PrO-DMT experience carries the full-spectrum serotonergic psychedelic signature. Visual, cognitive, emotional, and somatic dimensions coactivate rather than emerging in isolation, and the qualitative character is shaped more by psychological set and environmental setting than by dose alone. At lower doses, the experience centers on perceptual brightening, gentle introspective shifts, and emotional openness; at higher doses, the architecture of ordinary selfhood destabilizes — ego dissolution and profound alterations in the sense of time and meaning become defining features.

Community reports describe an experience qualitatively indistinguishable from psilocybin or psilacetin, consistent with all three compounds converging on the same active metabolite.[1] Some users report a marginally slower onset than psilacetin — a claim unconfirmed by pharmacokinetic data. The overall character aligns with the tryptamine psychedelic family: warmer and more inward-turning than LSD, with a less electrically stimulating body feel.

Effect Grid

Dose Level:
Description

Clear psychedelic effects become established. Geometry emerges alongside color enhancement, visual drifting, and environmental patterning. Emotional enhancement and introspection enhancement deepen substantially. Time alteration becomes noticeable — minutes may feel stretched or compressed. Thought connectivity increases, with ideas linking in novel ways. Cognitive euphoria is common.

Body high is prominent, with warmth, spontaneous body sensations, and tingling. Nausea is more likely, particularly during the come-up phase. Motor control impairment becomes noticeable, and pupil dilation is pronounced. Yawning and watery eyes may occur.

Set and setting become important determinants of experience quality. Cognitive flexibility increases, but decision-making is mildly impaired. Plan for 4–8 hours of reduced functional capacity.

Modeled from the effect's dose-dependence curve — not per-substance measurements.
Perception(47)likelihood · intensity
Geometry
likely
Holotropic state
likely
Color alteration
likely
Color enhancement
likely
Music enhancement
likely
Visual breathing
likely
Visual drifting
likely
Auditory enhancement
possible
Double vision!
rare

Music enhancement · Visual breathing · Visual drifting · Auditory enhancement · Brightness alteration · Environmental patterning · Perspective distortion · Tracers · Visual morphing · After-images · Auditory misinterpretation · Light sensitivity · Peripheral vision distortion · Sound sensitivity · Symmetrical texture repetition · Visual diffraction · Visual melting · Depth perception distortion · Proprioceptive distortion · Spatial disorientation · Visual haze / noise · Auditory distortion · Dreaming enhancement · Ganzfeld effect · Peripheral misidentification · Synesthesia · Touch enhancement · Vestibular distortion · Visual processing acceleration · Visual magnification · Visual acuity enhancement · Internal hallucinations · Object transformations · Flashbacks · Object activation · Visual recursion · Environmental orbism / cubism · Perspective hallucinations · Visual flipping · Auditory hallucinations · External hallucinations · Persisting hallucinations

Brightness alteration · Environmental patterning · Perspective distortion · Tracers · Visual morphing · After-images · Auditory misinterpretation · Light sensitivity · Peripheral vision distortion · Sound sensitivity · Symmetrical texture repetition · Visual diffraction · Visual melting · Depth perception distortion · Proprioceptive distortion · Spatial disorientation · Visual haze / noise · Auditory distortion · Dreaming enhancement · Ganzfeld effect · Peripheral misidentification · Synesthesia · Touch enhancement · Vestibular distortion · Visual processing acceleration · Visual magnification · Visual acuity enhancement · Internal hallucinations · Object transformations · Flashbacks · Object activation · Visual recursion · Environmental orbism / cubism · Perspective hallucinations · Visual flipping · Auditory hallucinations · External hallucinations · Persisting hallucinations

Body(36)likelihood · intensity
Pupil dilation
likely
Body high
possible
Spontaneous body sensations
possible
Appetite suppression
possible
Body schema distortion
possible
Laughter fits
possible
Stimulation
possible
Motor control impairment!
possible
Temperature dysregulation!
possible

Appetite suppression · Body schema distortion · Laughter fits · Stimulation · Tingling / electric sensations · Vibrations / buzzing · Nausea · Bodily heaviness · Physical fatigue · Tactile euphoria · Dizziness · Headache · Heart rate perception changes · Wakefulness · Bodily lightness · Bodily pressures · Muscle relaxation · Restlessness · Breathing alteration · Excessive sweating · Insomnia · Muscle tension · Nystagmus (eye wobbles) · Sedation · Involuntary body movements · Sexual arousal enhancement · Diarrhea · Trembling · Vomiting · Bodily dissociation · Tactile hallucination

Tingling / electric sensations · Vibrations / buzzing · Nausea · Bodily heaviness · Physical fatigue · Tactile euphoria · Dizziness · Headache · Heart rate perception changes · Wakefulness · Bodily lightness · Bodily pressures · Muscle relaxation · Restlessness · Breathing alteration · Excessive sweating · Insomnia · Muscle tension · Nystagmus (eye wobbles) · Sedation · Involuntary body movements · Sexual arousal enhancement · Diarrhea · Trembling · Vomiting · Bodily dissociation · Tactile hallucination

Thinking(39)likelihood · intensity
Aesthetic enhancement
likely
Introspection enhancement
likely
Novelty enhancement
likely
Cognitive euphoria
possible
Cognitive flexibility
possible
Conceptual thinking
possible
Suggestibility enhancement!
possible
Decision impairment!
possible
Amnesia!
v.rare

Cognitive euphoria · Cognitive flexibility · Conceptual thinking · Immersion enhancement · Multiple thought streams · Openness enhancement · Pattern recognition enhancement · Thought connectivity · Increased nature relatedness · Cognitive impairment · Thought loops · Creativity enhancement · Humor enhancement · Cognitive fatigue · Focus suppression · Memory replays · Synchronicity · Thought acceleration · Confusion · Information processing suppression · Thought disorganization · Analysis enhancement · Memory fragmentation · Thought deceleration · Analysis suppression · Cognitive dysphoria · Language suppression · Memory suppression · Focus enhancement · Information processing enhancement · Motivation enhancement · Amnesia · Delirium · Delusions

Immersion enhancement · Multiple thought streams · Openness enhancement · Pattern recognition enhancement · Thought connectivity · Increased nature relatedness · Cognitive impairment · Thought loops · Creativity enhancement · Humor enhancement · Cognitive fatigue · Focus suppression · Memory replays · Synchronicity · Thought acceleration · Confusion · Information processing suppression · Thought disorganization · Analysis enhancement · Memory fragmentation · Thought deceleration · Analysis suppression · Cognitive dysphoria · Language suppression · Memory suppression · Focus enhancement · Information processing enhancement · Motivation enhancement · Delirium · Delusions

Feeling(12)likelihood · intensity
Emotional enhancement
likely
Euphoria
possible
Emotional lability
possible
Catharsis
possible
Empathy enhancement
possible
Simultaneous emotions
possible
Anxiety
possible
Depression!
rare
Paranoia!
rare

Catharsis · Empathy enhancement · Simultaneous emotions · Anxiety · Anxiety suppression · Irritability · Dysphoria

Anxiety suppression · Irritability · Dysphoria

Self(22)likelihood · intensity
Emotional susceptibility
possible
Derealization
possible
Depersonalization
possible
Social connection
possible
Trust enhancement
possible
Flow state
possible
Sociability enhancement
possible
Compulsive behavior reduction
possible
Self-control suppression!
v.rare

Trust enhancement · Flow state · Sociability enhancement · Compulsive behavior reduction · Sociability suppression · Communication suppression · Disinhibition · Dissociation · Social disconnection · Communication enhancement · Automaticity · Ego inflation · Boundary dissolution · Ego dissolution · Identity alteration · Cognitive disconnection · Telepathic feelings

Sociability suppression · Communication suppression · Disinhibition · Dissociation · Social disconnection · Communication enhancement · Automaticity · Ego inflation · Boundary dissolution · Ego dissolution · Identity alteration · Cognitive disconnection · Telepathic feelings

Time(6)likelihood · intensity
Time alteration
likely
Present-moment absorption
possible
Temporal disorientation
possible
Deja vu
possible
Jamais vu
rare
Time cessation
v.rare

Time cessation

Transpersonal(12)likelihood · intensity
Unity and interconnectedness
possible
Existential realization
rare
Noetic insight
rare
Transpersonal feelings
rare
Entity contact
v.rare
Non-dual awareness
v.rare
Transpersonal visions
v.rare
Cessation
v.rare
Transpersonal memory access
v.rare

Non-dual awareness · Transpersonal visions · Cessation · Transpersonal memory access · Voidness · Death-rebirth sequence · Near-death experience

Voidness · Death-rebirth sequence · Near-death experience

Awareness(7)likelihood · intensity
Personal insight
likely
Lucid dreaming enhancement
possible
Mindfulness enhancement
possible
Lucidity enhancement
possible
Cognitive dissonance
possible
Reality testing impairment!
rare
Recursive awareness
rare

Cognitive dissonance · Recursive awareness

report missing effect
Likelihood: how common this effect is at the selected dose level.This effect has safety implications — review before use.

Timeline

Subjective Effects[edit]

The 4-PrO-DMT experience activates visual, cognitive, emotional, and somatic dimensions simultaneously. At lower doses the experience centers on perceptual brightening and emotional openness; at higher doses the ordinary sense of self dissolves. Psychological state and physical environment shape the experience more than dose alone.

Community reports describe it as indistinguishable from psilocybin or psilacetin[1] — consistent with all three converging on the same active metabolite. It sits within the tryptamine psychedelic family: warmer and more inward-turning than LSD, with less of the electrical stimulation LSD tends to produce.

Safety[edit]

Harm
Acute toxicity
Low
Chronic toxicity
Low
Withdrawal
None
Tolerance buildup
rapid
Tolerance reset
14 days
Dependence
Physical
None
Psychological
Negligible
Compulsive redosing
Negligible
Dose escalation
Negligible
Cross-tol.
psilo · psilocin · 4-AcO-DMT
Risk Shape
TOXPHYPSYWDRREDTOL

Toxicity

Acute toxicity

No acute toxicity studies exist for 4-PrO-DMT, and no human fatalities have been attributed to it.[3][4] The psilocin class has a therapeutic index of approximately 1,000:1 — an extremely wide gap between active and toxic doses.[5][14]

Typical transient effects at psychoactive doses include raised blood pressure, faster heart rate, dilated pupils, and nausea.[14]

Heart and circulation

4-PrO-DMT has unexpectedly strong binding at a serotonin receptor variant (5-HT₂B) — tighter than its grip on the main psychedelic target.[2] Prolonged 5-HT₂B activation is how fenfluramine and similar drugs damage heart valves.[15]

The practical risk is lower than it appears: 4-PrO-DMT converts to psilocin before reaching sustained exposure, and psychedelic use is rarely chronic.[15] Whether the prodrug can reach cardiac 5-HT₂B receptors before conversion completes is still unknown. safety citation needed

Psychological risks

High doses or psychiatric vulnerability can produce acute distress — panic, confusion, paranoia, and brief psychotic symptoms.[14] These are class effects of serotonergic psychedelics, shaped by psychological state, environment, dose, and individual psychiatric history.

Visual snow, halos, and geometric afterimages persisting weeks to months after use have been documented across the psychedelic class — rare, but likely underreported.[16]

Tolerance & dependence

Tolerance builds quickly. Daily use triggers serotonin receptor desensitization within a few days.[17][13] All classical serotonergic psychedelics share cross-tolerance — including psilocybin, LSD, mescaline, and DMT. Sensitivity returns within 1–2 weeks of stopping. inferred

Dependence is not a feature of this class. Neither physical nor psychological dependence develops from serotonergic psychedelic use.[18][19] No case reports describe 4-PrO-DMT withdrawal or compulsive use patterns.

Drug interactions

All known interaction risks come from psilocin research — no 4-PrO-DMT-specific studies exist.

MAOIs block serotonin breakdown, creating conditions for dangerous serotonin overload.[20] A case report documented a hypertensive emergency and heart attack when an MAOI was combined with psilocybin mushrooms.[21]

Lithium combined with classic psychedelics carries a high seizure risk. Analysis of 62 reports found 47% involved seizures and 39% required medical attention.[22] Zero of 34 lamotrigine + psychedelic reports involved seizures.[22]

SSRIs dampen the psychedelic effect by competing at serotonin receptors.[14] This blunting can drive dose escalation — which carries its own risks.

Tricyclic antidepressants may intensify the experience through enhanced serotonin and norepinephrine signaling.[14]

Contraindications

8 known
4ABSOLUTE
4RELATIVE

The following are derived from the psilocin/psilocybin class. 4-PrO-DMT has no substance-specific contraindication data.

Absolute:

Relative:

  • Active heart conditions — transient blood pressure and heart rate increases are class effects; the unresolved 5-HT₂B affinity of 4-PrO-DMT adds additional uncertainty[2][15]
  • Borderline personality disorder — emotional lability may be intensified[14]
  • Current tricyclic antidepressant use — potential enhancement of intensity[14]
  • Current SSRI use — blunted effects may lead to compensatory dose escalation[14]

Harm Reduction[edit]

Forms & Identification

Reagent ResultsNot recorded Add reagent results
AppearanceNot recorded Add appearance
Red FlagsNot recorded Add red flags
Full identification analysis →

4-PrO-DMT circulates as a white to off-white powder or pellet from online research chemical vendors. It is visually indistinguishable from dozens of other tryptamine powders, including far more potent substances.

A positive Ehrlich test (purple reaction) confirms an indole compound is present, but cannot distinguish 4-PrO-DMT from psilocybin, psilacetin, DMT, or other tryptamines. Quantitative analysis through an analytical testing service is the only reliable method for confirming identity and dose. Volumetric dosing from a calibrated solution is the most precise method in this potency range — eyeballing powder risks significant over- or under-dosing.

Set & setting

The quality of the experience is profoundly shaped by psychological state and physical environment. A calm, familiar, private space with access to comfort reduces the likelihood of anxious reactions. Beginning rested and in a positive mental state, with clear intentions, supports a constructive experience.

An experienced, sober companion is strongly recommended, especially for first-time use or higher doses. The companion's role is calm reassurance — not directing the experience — and intervening only if physical safety is at risk.

Guidelines

  • Test all material with an Ehrlich reagent at minimum. Send a sample to an analytical testing service when possible.
  • Use a milligram-precision scale (0.001 g) or prepare a volumetric solution for accurate dosing.
  • Start with a threshold or light dose on first use to assess individual sensitivity — especially given the absence of human pharmacokinetic data.
  • Eat lightly or fast for 2–3 hours before ingestion to reduce nausea.
  • Clear the schedule for the full duration with no obligations or driving.
  • Keep water, light food, and a change of environment available.
  • Wait at least 1–2 weeks between sessions to allow full tolerance recovery.

Aftercare & Integration

The days following a psychedelic experience often bring residual emotional sensitivity and new perspectives. This window is an opportunity to process the experience through reflection, conversation, or creative expression.

Journaling within the first 24–48 hours helps preserve insights before they fade. Talking with a trusted person can ground difficult material. For experiences that surface unresolved trauma or intense emotion, a therapist trained in psychedelic integration can provide structured support.

Recovery & Support

Serotonergic psychedelics carry low dependence potential, and compulsive 4-PrO-DMT use is not documented. Frequent psychedelic use can sometimes reflect avoidance of underlying difficulties rather than genuine exploration. If use is interfering with daily functioning, relationships, or mental health, professional support is appropriate.

Resources include the Fireside Project (62-FIRESIDE / 623-473-7433) for psychedelic peer support, and local mental health services.

Recovery resources, crisis lines, and support pathways → View all

Emergency Response

Recognizing an emergency: Most difficult psychedelic experiences are distressing but not medically dangerous. Signs requiring immediate help include: self-harm behavior or expressed intent, complete disconnection from reality with inability to respond to verbal cues, seizures, sustained chest pain, or loss of consciousness.

Immediate steps:

  • Call emergency services (911 / 112 / local equivalent) if the person is seizing, unresponsive, expressing intent to harm themselves, or experiencing sustained chest pain.
  • Move the person to a quiet, safe space. Remove hazards.
  • Speak calmly and simply. Reassure them that the effects are temporary and will pass.
  • Do not restrain the person unless they are in immediate danger of harming themselves or others.
  • Monitor breathing and body temperature until help arrives.

What to tell the dispatcher: State the substance name (4-PrO-DMT, a tryptamine psychedelic), the approximate amount taken, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect callers who seek medical help during a drug-related emergency.

Frequently asked questions

What is 4-PrO-DMT?

4-PrO-DMT is a synthetic substituted tryptamine that functions as a prodrug of psilocin, the psychoactive metabolite of psilocybin. First pharmacologically characterized in 2023, it converts to psilocin via esterase-mediated hydrolysis.

How long does 4-PrO-DMT last?

Total duration by route of administration — Oral: 4 – 8 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.

Where can I find dosage information for 4-PrO-DMT?

Psychedex publishes a dosage table for 4-PrO-DMT on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.

Is 4-PrO-DMT addictive?

Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for 4-PrO-DMT: tolerance builds rapid; full reset takes 14 days; cross-tolerance develops with psilocybin, psilocin, 4-AcO-DMT, LSD, mescaline, DMT. See the article's dependence and safety sections for recorded dependence data.

Safety[edit]

Harm
Acute toxicity
Low
Chronic toxicity
Low
Withdrawal
None
Tolerance buildup
rapid
Tolerance reset
14 days
Dependence
Physical
None
Psychological
Negligible
Compulsive redosing
Negligible
Dose escalation
Negligible
Cross-tol.
psilo · psilocin · 4-AcO-DMT
Risk Shape
TOXPHYPSYWDRREDTOL

Toxicity

Acute toxicity

No controlled toxicity data exist for 4-PrO-DMT, and no human fatalities have been attributed to the compound.[3][4] The active metabolite psilocin has a wide margin between active and lethal doses in animal models — the estimated therapeutic index for the psilocybin class is approximately 1,000:1.[5][17]

In mice, 4-PrO-DMT produces psychedelic-like effects at 0.3–3 mg/kg (subcutaneous), while sedation and temperature drops emerge at 3–30 mg/kg.[2] Transient physiological effects expected at psychoactive doses include blood pressure elevation, increased heart rate, pupil dilation, and nausea.[17]

Heart and circulation

4-PrO-DMT binds 5-HT₂B receptors with unexpectedly high affinity — substantially stronger at this target than at the primary psychedelic receptor 5-HT₂A.[2] Chronic activation of 5-HT₂B is the established mechanism behind heart valve damage associated with drugs like fenfluramine.[18]

Three factors reduce the practical relevance of this finding: 4-PrO-DMT converts to psilocin (which has lower 5-HT₂B affinity) before reaching steady-state exposure; psychedelic use is typically intermittent rather than chronic; and clinical psilocybin studies have demonstrated relative cardiovascular safety.[18] Whether the intact prodrug molecule engages cardiac 5-HT₂B receptors before hydrolysis is complete remains an unresolved safety question. safety citation needed

Psychological risks

Acute psychological distress — including anxiety, confusion, paranoia, and transient psychotic-like symptoms — can occur at high doses or in unprepared individuals.[17] These reactions are a class effect of serotonergic psychedelics, influenced by psychological set, environmental setting, dose, and individual psychiatric vulnerability. No substance-specific psychological adverse event data exist for 4-PrO-DMT.

Hallucinogen persisting perception disorder (HPPD) — enduring visual disturbances such as visual snow, halos, and geometric afterimages persisting weeks to months after use — has been documented across the serotonergic psychedelic class.[19] The condition appears rare but may be underreported.

Persons with a personal or family history of schizophrenia, schizoaffective disorder, or bipolar I disorder face elevated risk of prolonged or severe psychotic episodes and should not use 4-PrO-DMT.[17]

Tolerance & dependence

Tolerance develops rapidly. Repeated 5-HT₂A agonism causes receptor downregulation and functional desensitization within days of consecutive use.[20][15] Cross-tolerance is expected with all classical serotonergic psychedelics, including psilocybin, LSD, mescaline, and DMT. Receptor sensitivity is expected to recover within 1–2 weeks of abstinence. inferred

Dependence does not develop. Serotonergic psychedelics as a class produce neither physical nor psychological dependence.[21][22] No published case reports describe 4-PrO-DMT dependence, withdrawal, or compulsive use patterns.

Drug interactions

The interaction profile is inferred from psilocin. No substance-specific interaction studies exist.

MAOIs: The highest-risk combination. Monoamine oxidase inhibitors impair serotonin metabolism, creating conditions for serotonin toxicity.[23] A case report documented a hypertensive emergency and heart attack in a patient taking tranylcypromine and dextroamphetamine who consumed psilocybin mushrooms.[24]

Lithium: Analysis of 62 reports of classic psychedelics combined with lithium found that 47% involved seizures and 39% required medical attention.[25] By contrast, zero of 34 lamotrigine + psychedelic reports involved seizures.[25]

SSRIs: May blunt the psychedelic effect through competition at serotonin receptors. Blunted effects can lead to compensatory dose escalation.[17]

Tricyclic antidepressants: May intensify the experience through serotonin and norepinephrine reuptake inhibition.[17]

Contraindications

8 known
4ABSOLUTE
4RELATIVE

The following contraindications are derived from the psilocin/psilocybin class. No substance-specific data exist for 4-PrO-DMT.

Absolute:

Relative:

  • Active heart conditions — transient blood pressure and heart rate increases are class effects; the unresolved 5-HT₂B affinity of 4-PrO-DMT adds additional uncertainty[2][18]
  • Borderline personality disorder — emotional lability may be intensified[17]
  • Current tricyclic antidepressant use — potential enhancement of intensity[17]
  • Current SSRI use — blunted effects may lead to compensatory dose escalation[17]

Harm Reduction[edit]

Forms & Identification

Reagent ResultsNot recorded Add reagent results
AppearanceNot recorded Add appearance
Red FlagsNot recorded Add red flags
Full identification analysis →

4-PrO-DMT circulates almost exclusively as a white to off-white powder or pellet sold through online research chemical vendors. Because the compound is visually indistinguishable from dozens of other tryptamine powders — including far more potent substances — reagent testing alone cannot confirm identity. A positive Ehrlich result (purple reaction) indicates the presence of an indole but cannot distinguish 4-PrO-DMT from psilocybin, psilacetin, DMT, or other tryptamines.

Quantitative analysis through an analytical testing service is the only reliable method for confirming that the substance and dose match what was sold. Volumetric dosing from calibrated solutions is the most reliable way to measure doses in this potency range — eyeballing powder is unreliable and risks significant over- or under-dosing.

Set & setting

As with all serotonergic psychedelics, the quality of the 4-PrO-DMT experience is profoundly shaped by psychological state (set) and physical environment (setting). A calm, familiar, private space with access to nature or comfort objects reduces the likelihood of anxious reactions. Beginning in a positive, rested mental state with clear intentions supports a constructive experience.

An experienced, sober companion ("trip sitter") is strongly recommended, especially for first-time users or higher doses. The sitter's role is to provide calm reassurance without directing the experience, and to intervene only if physical safety is at risk.

Guidelines

  • Test all material with an Ehrlich reagent at minimum. Send a sample to an analytical testing service when possible.
  • Use a milligram-precision scale (0.001 g) or prepare a volumetric solution for accurate dosing.
  • Start with a threshold or light dose on first use to assess individual sensitivity — especially given the absence of human pharmacokinetic data.
  • Eat lightly or fast for 2–3 hours before ingestion to reduce nausea.
  • Clear the schedule for the full duration with no obligations or driving.
  • Keep water, light food, and a change of environment available.
  • Wait at least 1–2 weeks between sessions to allow full tolerance recovery.

Aftercare & Integration

The days following a psychedelic experience often carry a residual openness — emotional sensitivity, novel perspectives, and sometimes vulnerability. This window is an opportunity for integration: processing the experience through reflection, conversation, or creative expression.

Journaling thoughts and emotions within the first 24–48 hours helps preserve insights before they fade. Talking with a trusted friend or experienced peer can ground difficult material. For experiences that surface unresolved trauma or intense emotion, a therapist trained in psychedelic integration can provide structured support.

Recovery & Support

Serotonergic psychedelics as a class carry low dependence potential, and compulsive 4-PrO-DMT use is not documented. However, patterns of frequent psychedelic use can reflect avoidance of underlying psychological difficulties rather than genuine exploration. If psychedelic use is interfering with daily functioning, relationships, or mental health, professional support is warranted.

Resources include the Fireside Project (62-FIRESIDE / 623-473-7433) for psychedelic peer support, and local mental health services.

Recovery resources, crisis lines, and support pathways → View all

Emergency Response

Recognizing an emergency: Most difficult psychedelic experiences are distressing but not medically dangerous. Signs that require immediate help include: self-harm behavior or expressed intent, complete disconnection from reality with inability to respond to verbal cues, seizures, sustained chest pain, or loss of consciousness.

Immediate steps:

  • Call emergency services (911 / 112 / local equivalent) if the person is seizing, unresponsive, expressing intent to harm themselves, or experiencing sustained chest pain.
  • Move the person to a quiet, safe space. Remove hazards.
  • Speak calmly and simply. Reassure them that the effects are temporary and will pass.
  • Do not restrain the person unless they are in immediate danger of harming themselves or others.
  • Monitor breathing and body temperature until help arrives.

What to tell the dispatcher: State the substance name (4-PrO-DMT, a tryptamine psychedelic), the approximate amount taken, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect callers who seek medical help during a drug-related emergency.

Frequently asked questions

What is 4-PrO-DMT?

4-PrO-DMT is a synthetic substituted tryptamine that functions as a prodrug of psilocin, the psychoactive metabolite of psilocybin. First pharmacologically characterized in 2023, it converts to psilocin via esterase-mediated hydrolysis.

How long does 4-PrO-DMT last?

Total duration by route of administration — Oral: 4 – 8 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.

Where can I find dosage information for 4-PrO-DMT?

Psychedex publishes a dosage table for 4-PrO-DMT on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.

Is 4-PrO-DMT addictive?

Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for 4-PrO-DMT: tolerance builds rapid; full reset takes 14 days; cross-tolerance develops with psilocybin, psilocin, 4-AcO-DMT, LSD, mescaline, DMT. See the article's dependence and safety sections for recorded dependence data.

experience reportsview all →

No experience reports yet. Be the first to contribute.

First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.

references

  1. [1] 
    ^abcdRakoczy RJ, Runge GN, Sen AK, et al. (2024) Pharmacological and behavioural effects of tryptamines present in psilocybin-containing mushrooms — British Journal of Pharmacology doi:10.1111/bph.16466
  2. [2] 
    ^abcdefghijkGlatfelter GC, Naeem M, Pham DNK, Golen JA, Chadeayne AR, Manke DR, Baumann MH (2023) Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice — ACS Pharmacology & Translational Science doi:10.1021/acsptsci.2c00222
  3. [3] 
    ^abcdefghijklmWikipedia contributors (2024) 4-PrO-DMT Link
  4. [4] 
    ^abPsychonautWiki contributors (2024) 4-PrO-DMT Link
  5. [5] 
    ^abZhuk O, Jasicka-Misiak I, Poliwoda A, Kazakova A, Godovan VV, Halama M, Wieczorek PP (2015) Research on acute toxicity and the behavioral effects of methanolic extract from psilocybin mushrooms and psilocin in mice — Toxins doi:10.3390/toxins7041018
  6. [6] 
    ^Tittarelli R, Mannocchi G, Pantano F, Romolo FS (2015) Recreational use, analysis and toxicity of tryptamines. — Current neuropharmacology doi:10.2174/1570159x13666141210222409

references

  1. [1] 
    ^abcdRakoczy RJ, Runge GN, Sen AK, et al. (2024) Pharmacological and behavioural effects of tryptamines present in psilocybin-containing mushrooms — British Journal of Pharmacology doi:10.1111/bph.16466
  2. [2] 
    ^abcdefghijklmnoGlatfelter GC, Naeem M, Pham DNK, Golen JA, Chadeayne AR, Manke DR, Baumann MH (2023) Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice — ACS Pharmacology & Translational Science doi:10.1021/acsptsci.2c00222
  3. [3] 
    ^abcdefghijklmWikipedia contributors (2024) 4-PrO-DMT Link
  4. [4] 
    ^abPsychonautWiki contributors (2024) 4-PrO-DMT Link
  5. [5] 
    ^abZhuk O, Jasicka-Misiak I, Poliwoda A, Kazakova A, Godovan VV, Halama M, Wieczorek PP (2015) Research on acute toxicity and the behavioral effects of methanolic extract from psilocybin mushrooms and psilocin in mice — Toxins doi:10.3390/toxins7041018
  6. [6] 
    ^Tittarelli R, Mannocchi G, Pantano F, Romolo FS (2015) Recreational use, analysis and toxicity of tryptamines. — Current neuropharmacology doi:10.2174/1570159x13666141210222409
History|EvidenceLast updated Sep 17, 2026